Investor Presentaiton
Company overview
Financial performance
Oncology
Financial review
2022 priorities
Appendix
Innovation: Pipeline overview
Innovation: Clinical trials
Immunology
Ophthalmology
Neuroscience
Respiratory Disease
remibrutinib - BTK inhibitor
NCT04109313 (CLOU064A2201E1)
Chronic spontaneous urticaria (CSU)
Indication
Phase
Phase 2
Patients
250
Primary
Long-term safety and tolerability
Selected dose of LOU064 taken orally twice a day (morning and evening)
from day 1 to week 52
Patients with CSU who have participated in preceding studies with LOU064
Outcome
Measures
Arms
Intervention
Target
Patients
Read-out
Milestone(s)
H2 2022
Publication
Primary 2023
References
Abbreviations
Cardio-Renal
Global Health
Biosimilars
73 Investor Relations | Q2 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation